• Company
  • News
  • Investors
  • Contacts
  • Careers
polypeptide-logopolypeptide-logologo-mobilepolypeptide-logo
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Generic peptides
✕
  • Home
  • News
  • Media releases
  • PolyPeptide announces results of the annual General Meeting 2026

PolyPeptide announces results of the annual General Meeting 2026

8 April 2026
Media releases

Baar, 8 April 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all proposals put forward by the Board of Directors at the Company’s fifth annual General Meeting with a large majority.

The Chair of the Board of Directors of PolyPeptide Group AG (the “Company”), Peter Wilden, welcomed the shareholders at the Company’s fifth annual General Meeting (“AGM 2026”) that took place at the Chollerhalle in Zug. At the AGM 2026, a total of 26,780,855 shares with voting rights were represented, corresponding to 80.85% of the issued registered shares of the Company.

All six members of the Board of Directors proposed for re-election were appointed for a term of office ending at the conclusion of the next annual General Meeting 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting 2027.

Further proposals of the Board of Directors that were approved at the AGM 2026 included, among others, the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders also granted discharge to all members of the Board of Directors and Executive Committee in office in the financial year 2025 for their activities in the financial year 2025. The shareholders approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2025 as well as the Remuneration Report 2025 in a separate consultative vote.

The minutes of the AGM 2026 will be available within 15 days here
The next annual General Meeting 2027 will be held on 7 April 2027.

[…]

Download PDF (English)

Download PDF (German)

Back to news

Related posts

19 March 2026

PolyPeptide strengthens financing structure through expansion of existing credit facility


Read more
17 March 2026

PolyPeptide publishes invitation to the annual General Meeting 2026


Read more
12 December 2025

PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2026 PolyPeptide Group • Cookie Policy • Sitemap • Privacy policy
    • Company
    • News
    • Investors
    • Contacts
    • Careers